<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188588</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01244-47</org_study_id>
    <nct_id>NCT03188588</nct_id>
  </id_info>
  <brief_title>Observance of Long Term Oxygen Therapy in Chronic Inspiratory Disease Patients</brief_title>
  <acronym>ObsO2</acronym>
  <official_title>Observance of Long Term Oxygen Therapy in Chronic Inspiratory Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOS Oxygene Mediterranee</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU Arnaud de Villeneuve MONTPELLIER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SOS Oxygene Mediterranee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term oxygen therapy (LTOT) is the reference treatment for chronic respiratory failure.&#xD;
      This treatment is based on the principle of oxygen supplementation via a source to correct&#xD;
      hypoxemia in patients. At present, adherence to this treatment is difficult to evaluate&#xD;
      (reporting by patients), but the results of the literature show poor LTOT compliance. It is&#xD;
      therefore important to accurately measure the oxygen consumption by patients and to&#xD;
      understand the factors explaining LTOT compliance. The ultimate aim is to improve our patient&#xD;
      management to make them more observant in order to improve the therapeutic efficacy of the&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oxygen use</measure>
    <time_frame>6 month</time_frame>
    <description>time of oxygen use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>respiratory disease severity based on GOLD standards</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessed by a questionnaire (VQ-11)</measure>
    <time_frame>baseline, 3 month and 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>precarity score assessed by a questionnaire (EPICE)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">120</enrollment>
  <condition>Chronic Respiratory Disease</condition>
  <condition>Hypoxemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients are recruited from pneumologia unit of hospital and from private pneumologists&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic respiratory disease patients with chronic hypoxemia&#xD;
&#xD;
          -  First prescribed long term oxygenotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with NIV and CPAP&#xD;
&#xD;
          -  vital pronostic &lt; 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Bourdin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

